Sanyou Biopharmaceuticals Introduces GEOTA Platform for Drug Research

July 10, 2026
Sanyou Biopharmaceuticals has released GEOTA 1.0, a new digital computing platform within its SAI-DA program that simplifies access to AI-driven research tools for drug development.

Sanyou Biopharmaceuticals has introduced GEOTA 1.0, a new digital computing platform designed to support drug research and development, announced in a press release. GEOTA is part of the company's SAI-DA (Sanyou AI-Drug Accelerator) program and serves as an upgrade to its intelligent R&D framework.

According to the company, GEOTA decouples complex AI algorithms into a simplified web interface that allows researchers to access computing functions without coding or bioinformatics expertise. This approach aims to make advanced digital tools more accessible for use in laboratory research and drug discovery.

The first batch of GEOTA's core functions is now open for trial. This release builds on Sanyou's AI-STAL molecular library and its ongoing efforts to improve efficiency and reduce the time required for drug innovation.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

07/10
RyboDyn Awarded $1.3 Million Grant from U.S. Department of War for Lung Cancer Therapies
07/10
Lucile Packard Children's Hospital Deploys R-Zero Physical AI for Energy Optimization
07/10
Children’s Hospital of Philadelphia Receives $38.9 Million ARPA-H Award for Personalized Gene Editing Research
07/10
Collectly Launches AI Billing Integration on Epic Connection Hub
07/09
Movemedical Introduces Ask Move AI Assistant for Medical Device Field Operations

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like